Search

Cellavision AB

Abrir

154.6 -1.78

Visão Geral

Variação de preço das ações

24h

Atual

Mín

152.6

Máximo

158.6

Indicadores-chave

By Trading Economics

Rendimento

-17M

31M

Vendas

-16M

176M

P/E

Médio do Setor

25.197

79.657

EPS

1.31

Rendimento de Dividendos

1.51

Margem de lucro

17.843

Funcionários

219

EBITDA

-15M

52M

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

1.51%

3.27%

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

138M

4.3B

Abertura anterior

156.38

Fecho anterior

154.6

Cellavision AB Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

17 de nov. de 2025, 18:59 UTC

Grandes Movimentos do Mercado

Medicus Pharma Shares Rise After Filing of FDA Priority-Voucher Application

17 de nov. de 2025, 23:40 UTC

Conversa de Mercado

Gold Consolidates Amid Mixed Signals -- Market Talk

17 de nov. de 2025, 23:34 UTC

Conversa de Mercado

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

17 de nov. de 2025, 22:58 UTC

Conversa de Mercado

RBA's Easing Cycle Is Done, TD Securities Says -- Market Talk

17 de nov. de 2025, 22:46 UTC

Conversa de Mercado

Risk Assets Set to Have a Strong 2026 -- Market Talk

17 de nov. de 2025, 22:06 UTC

Aquisições, Fusões, Aquisições de Empresas

Constellation Software's Harris Operating Group Completes Agreement To Acquire TECVIA Holding GmbH >CSU.T

17 de nov. de 2025, 22:02 UTC

Ganhos

Trip.com Group 3Q Rev $2.6B >TCOM

17 de nov. de 2025, 22:02 UTC

Ganhos

Trip.com Group 3Q Adj EPS $3.87 >TCOM

17 de nov. de 2025, 22:02 UTC

Ganhos

Trip.com Group 3Q EPS $4.02 >TCOM

17 de nov. de 2025, 21:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

17 de nov. de 2025, 21:40 UTC

Ganhos

James Hardie Industries 2Q Adj EPS 26c >JHX

17 de nov. de 2025, 21:40 UTC

Ganhos

James Hardie Industries 2Q Loss/Shr 10c >JHX

17 de nov. de 2025, 21:39 UTC

Ganhos

James Hardie Industries 2Q Sales $1.29B >JHX

17 de nov. de 2025, 21:38 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17 de nov. de 2025, 21:38 UTC

Ganhos

XPeng Earnings Beat Wall Street Estimates. Why the Stock Is Falling. -- Barrons.com

17 de nov. de 2025, 21:10 UTC

Ganhos

XP Inc. 3Q EPS BRL2.47 >XP

17 de nov. de 2025, 21:10 UTC

Ganhos

XP Inc. 3Q Rev BRL4.67B >XP

17 de nov. de 2025, 20:20 UTC

Conversa de Mercado

U.S. Natural Gas Retreats on Milder Weather Outlook -- Market Talk

17 de nov. de 2025, 20:12 UTC

Conversa de Mercado

Easing Underlying Inflation in Canada Seen Leaving Door Open to Rate Cuts Next Year -- Market Talk

17 de nov. de 2025, 20:12 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 de nov. de 2025, 20:09 UTC

Conversa de Mercado

Latest Canadian Inflation Data Supports View BoC is Done Cutting Rates This Cycle -- Market Talk

17 de nov. de 2025, 19:29 UTC

Conversa de Mercado

Gold Slide Continues to Start Week -- Market Talk

17 de nov. de 2025, 19:16 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17 de nov. de 2025, 18:20 UTC

Aquisições, Fusões, Aquisições de Empresas

Johnson & Johnson Will Buy Cancer Drugmaker Halda Therapeutics for $3.1 Billion -- Barrons.com

17 de nov. de 2025, 16:45 UTC

Aquisições, Fusões, Aquisições de Empresas

Oil Giant TotalEnergies Is Betting Big on Electricity -- Update

17 de nov. de 2025, 16:16 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17 de nov. de 2025, 16:15 UTC

Ganhos

Luckin, a Chinese Challenger to Starbucks, Aims to Return to U.S. Stock Market -- WSJ

17 de nov. de 2025, 15:40 UTC

Aquisições, Fusões, Aquisições de Empresas

Strategy Is in the Crosshairs of Crypto Investors. It Bought More Bitcoin Anyway. -- Barrons.com

17 de nov. de 2025, 15:22 UTC

Aquisições, Fusões, Aquisições de Empresas

Alphabet Stock Pops After Berkshire Takes Stake. Why Buffett Might Be Buying. -- Barrons.com

17 de nov. de 2025, 15:19 UTC

Conversa de Mercado

Deutsche Bank's Strategic Plan Looks a Tad Underwhelming -- Market Talk

Cellavision AB Previsão

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Cellavision AB

CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides CellaVision DM1200 and CellaVision DM9600, designs to automate and simplify the process of performing blood and body fluid differentials; CellaVision DC-1, an analyzer to enable low-volume hematology labs to implement CellaVisions digital methodology for performing blood cell; and DIFF-Line that automates and digitizes the process of analyzing peripheral blood smears. It also offers CellaVision Peripheral Blood Application that enables laboratories to automate, standardize, and simplify morphological examination of peripheral blood smears; CellaVision Advanced RBC Application, which enables to perform comprehensive examination of red blood cell morphology; CellaVision Body Fluid Application that enables laboratories to automate, standardize, and simplify morphological examination of body fluid preparations; and CellaVision Remote Review Software, which removes restrictive geographical constraints from the smear review process. In addition, the company provides CellaVision Server Software that creates a single streamlined workflow within one or multiple testing sites; CellaVision Proficiency Software, a web-based software designed to help laboratory managers assess, monitor, and promote staff competency in cell morphology; CellaVision CellAtlas, which combines a series of mini lectures with an extensive cell image library; and CellaVision VET that offers digital solutions for medical microscopy in the field of hematology. Further, the company offers reagents to identify cell and tissue morphology, parasites, and bacteria in diagnosing various diseases; and instruments, including RAL SmearBox, RAL Stainbox, and RAL Stainer. It sells its products to hospital and commercial laboratories. CellaVision AB (publ) was incorporated in 1994 and is headquartered in Lund, Sweden.
help-icon Live chat